Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $21.00.

Separately, HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 target price on the stock.

Artiva Biotherapeutics Price Performance

ARTV opened at $5.10 on Friday. The stock’s fifty day moving average is $5.59 and its 200-day moving average is $9.73. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently modified their holdings of ARTV. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth about $52,000. Wells Fargo & Company MN lifted its stake in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares in the last quarter. MetLife Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth about $135,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth approximately $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.